Oncology Featured Articles
-
Clinical News Roundup: What If You Set Up A Clinical Trial & Nobody Signs Up?
6/10/2016
Clinical News Roundup for the week of June 6, 2016 featuring new trial recruitment tools, breast cancer innovations, FDA guidelines on EHR data in trials, adaptive trials for Alzheimer’s treatments, and the NIH abandons clinical research centers.
-
IN CASE YOU MISSED IT: Clinical Leader Top 3 Articles For May 2016
6/5/2016
Below are my top three articles downloaded on Clinical Leader for the month of May 2016. In case you missed them, please take this opportunity to see what everyone else was learning about Merck’s efforts to be a sponsor of choice, FDAs decision on Eteplirsen, and BMS’ success in clinical trials for Opdivo.
-
ASCO To Take A Closer Look At Patient-Reported Outcomes In Clinical Trials And Cancer Care
6/2/2016
While the annual meetings of the American Society of Clinical Oncology (ASCO) can almost always be counted on to generate news about scientific breakthroughs in understanding and treating cancer, the theme for this year’s conference goes beyond that conventional approach. ASCO 2016 Annual Meeting will prominently feature discussions about how clinicians can best integrate recent advances, and particularly how to best assess the impact on real-world patients.
-
Clinical News Roundup: Will Changes To EU Legislation Improve Trials?
5/27/2016
Clinical news roundup for the week of May 22, 2016 with articles on EU legislation, five major trials set to announce results, BIO releases study on clinical success, trials in Australia, fear as a roadblock to oncology recruitment, and more.
-
As Lawmakers And FDA Consider Patient Diversity, What Can Sponsors Do?
5/27/2016
Patient diversity is currently an important topic in clinical trials. The low percentage of patient participation in trials has long been a concern, but the even lower participation rates of women and other demographic groups is a bigger concern. Legislators and the FDA are now looking into ways to make trial participation more representative of the general population, but can sponsors and CROs be doing more?
-
BMS’ Opdivo Trials: What They Teach Us About Successful Studies
5/17/2016
It’s hard to ignore the news around immunotherapies to treat cancer. Opdivo is a Bristol-Myers Squibb (BMS) medicine that has been approved by the FDA for patients with previously treated advanced non-small cell lung cancer (NSCLC), metastatic melanoma, and renal cell carcinoma. Opdivo also provides a textbook lesson for sponsor companies on how to conduct a successful clinical trial.
-
Clinical News Roundup: As Quintiles And IMS Health Merge, Should Sponsors Reevaluate Partnerships?
5/6/2016
Clinical Leader news roundup for the week of May 2, 2016, with articles on the merger between Quintiles and IMS Health, immuno-oncology awareness at BMS, digital human models in clinical research, matching cancer patients with trials, and more.
-
Can 21st Century Cures Increase Clinical Trial Awareness?
5/3/2016
A successful end may be in sight for Congress’ 21st Century Cures Act, which the U.S. Senate is expected to act upon in the coming weeks. The bill would expedite approval for drugs and medical devices and increase funding for medical research. It would also streamline clinical trials, an improvement if not quite a wholesale solution to clinical trials’ biggest impediment: chronic under-enrollment.
-
NEWS ROUNDUP: Santa Claus, The Easter Bunny, And Patient Centricity?
4/11/2016
Clinical Leader news roundup for the week of April 4, 2016, with articles on Patient recruitment via Twitter, NIH sponsors trial of anti-HIV antibody, diversity in clinical trials, INC Research partners with CISCRP, the use of apps in clinical trials, and the myth of patient centricity.
-
New Biologics Create Need For Patient-Friendly Injectors
3/8/2016
Analysts forecast that by the end of 2016, 50 percent of the top 100 drugs on the market will be biologics. Currently more than 900 biologic drugs are in development to treat a broad range of conditions, including cancers, immunologic disorders, and rare and chronic diseases. That the majority of new injectable treatments are biologics will present a new challenge in delivery of the medicines.